FFR,iFR,CFR和IMR:来自临床试验的结果
Cathevine Yang1, Christopher Wong1, Kosei Teradaa1
1Stanford University, Department of Medicine, Division of Cardiovascular Medicine, Stanford, CA, USA.
概括
本综述探讨了分量流量储备 (FFR),即时无波比 (iFR),冠状动脉流量储备 (CFR) 和微血管阻力指数 (IMR) 用于诊断和管理冠状动脉微血管功能障碍,并指出它们的局限性和新兴应用.
科学领域:
- 心脏病学 心脏病学
- 血管生理学 血管生理学
- 诊断成像 诊断成像 诊断成像
背景情况:
- 冠状动脉微血管功能障碍 (CMD) 越来越被认为是缺血性心脏病的重要贡献者.
- 准确的诊断和CMD的管理对于改善患者的治疗结果至关重要.
- 目前用于CMD的诊断工具和治疗策略需要进一步改进.
研究的目的:
- 提供用于评估冠状动脉疾病的关键生理指数的全面概述.
- 在CMD的背景下讨论FFR,iFR,CFR和IMR的定义,应用和限制.
- 审查各种心血管疾病中这些指数的最新证据和新出现的临床适用性.
主要方法:
- 系统审查关于FFR,iFR,CFR和IMR的当前文献.
- 对这些指数在CMD中的诊断和预后性能进行分析.
- 评估它们在治疗心脏上部和微血管冠状动脉疾病方面的有用性.
主要成果:
- FFR,iFR,CFR和IMR为冠状动力学和微血管功能提供了宝贵的见解.
- 每个指数都有特定的局限性,必须在临床实践中考虑.
- 新出现的证据支持它们在急性心肌梗塞,心力衰竭与保存的喷射分数以及移植后的环境中使用.
结论:
- FFR,iFR,CFR和IMR是评估CMD的重要工具,它们补充了传统的血管学.
- 了解它们的局限性和适当的应用是优化患者护理的关键.
- 需要进一步的研究,以充分阐明它们在复杂心血管情景中的作用.
相关概念视频
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:20Drug Product Performance: In Vitro–In Vivo Correlation
431
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
431
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:12Hazard Ratio
756
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
756